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Abstract
Aim The purpose of this study is to report a rare case of
cytomegalovirus (CMV) retinitis in a seronegative patient
with systemic lupus erythematosus (SLE) on immunosup-
pressive therapy.
Methods A seronegative patient with SLE who was on
immunosuppressive therapy developed CMV retinitis. The
immunosuppressive therapy was tapered, and the patient was
given intravitreal ganciclovir and foscarnet in addition to
systemic ganciclovir. The follow-up visits were documented.
Result The patient responded to the treatment and there was
complete resolution.
Conclusion CMV retinitis is a rapidly progressive condition
and patients on immunosuppressive therapy should be
referred to an ophthalmologist for periodic check-up for early
diagnosis and treatment of this devastating ophthalmic
condition. For clinically resistant CMV retinitis in seronega-
tive patients with SLE, a combination therapy of intravitreal
foscarnet with oral and intravenous ganciclovir is useful.
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Introduction
Systemic lupus erythematosus (SLE) is not generally
considered a predisposing factor for cytomegalovirus
(CMV) retinitis. Immunosuppressive therapy may have a
role in the development of CMV retinitis in these patients
[1]. We report a case of bilateral CMV retinitis in a
seronegative patient with systemic lupus erythematosus on
immunosuppressive therapy for grade 4 lupus nephritis.
Case report
In 2009, a 31-year-old female, known case of systemic lupus
erythematosus with stage IV lupus on immunosuppressive
therapy, presented with floaters and gradual painless progres-
sive diminution of vision more in the right eye than left eye
since 1 week. Two years earlier, in 2007, the patient had
developed fever, skin rashes, nausea, breathing difficulty,
polyarthralgias and myalgias. She had been admitted to a
hospital and had been diagnosed as SLE based on clinical
presentation and investigation results which were as follows:
anti-DNA positive (3.68); proteinuria, 4+; raised 24-h urine
protein, 5,432 mg/24 h (21.3–119.6 mg/24 h); ANA positive
(1.56); Ro-52 positive; raised C-reactive protein level, 30 mg/
L. The renal biopsy showed diffuse proliferative glomerulo-
nephritis with capillary wall thickening consistent with lupus
nephritis (WHO class IV) with activity index, 04; chronicity
index, 01. She had been given intravenous methyl predniso-
lone 1 g daily for 1 week, azathioprine tablet 50 mg twice a
day, hydroxychloroquine tablet 200 mg twice a day and
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DOI 10.1007/s12348-010-0017-3Fig. 1 The right eye showed a
ten-disc-diameter size yellowish
white lesion with hazy irregular
border at the posterior pole.
There was mild vitreous haze.
The left eye showed presence of
perivascular exudates, retinal
haemorrhages along the inferior
vessels with mild vitreous haze
Fig. 2 Haemorrhages and exu-
dates along the inferior arcade
disappeared in the left eye. The
right eye lesion, although, be-
came smaller
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1 mg/kg tapering every 7 days had been started after the
course of intravenous methyl prednisolone. The patient
improved and had been discharged.
She was regularly followed up and steroid maintenance
dose of 10 mg alternated with 5 mg continued in addition to
azathioprine 100 mg twice a day, mycophenolate mofetil
500 mg twice a day, hydroxychloroquine 200 mg once a
day, furosemide 10 mg twice a day and calcium supplement
500 mg twice a day. Renal function tests, hemogramme,
ESR, 24-h urinary proteins, liver function tests were done
periodically. She had no ophthalmic complaints till 2009. In
2009, the patient developed high-grade fever, urinary tract
infection and oral candidiasis. She was admitted in the
hospital and treated for the same. She was discharged after
1 week. At the time of discharge, the patient started
complaining of diminution of vision and floaters in the
right eye more than the left eye. She was then referred to
the ophthalmologist.
On ocular examination, the vision in the right eye was
finger counting 1 per metre and in the left eye it was 20/60.
The anterior segment and intraocular pressures were normal
in both eyes .On fundus examination, the right eye showed
a ten-disc-diameter size yellowish white lesion with hazy
irregular border at the posterior pole. There was mild
vitreous haze. The left eye showed presence of perivascular
exudates, retinal haemorrhages along the inferior arcade
with mild vitreous haze (Fig. 1). A clinical diagnosis of
bilateral CMV retinitis was made. There was no evidence of
systemic CMV infection.
Results of an enzyme-linked immunosorbent assay test for
antibodies to human immunodeficiency virus, hepatitis B and
C were negative, CMV IgM antibody was negative and IgG
was positive at an immune status ratio of 2.87 (0–0.90),
toxoplasma IgG, IgM and VDRL was negative. Blood culture
was negative for CMV. The absolute lymphocyte count was
680/mm
3, total leucocytic count, 10,700/mm
3; CD4, 81. The
polymerase chain reaction of the aqueous sample was
positive for CMV retinitis and negative for herpes simplex
virus and herpes zoster virus and toxoplasmosis. After
consultation with the rheumatologist, mycophenolate mofetil
was discontinued; azathioprine dose was reduced to 50 mg
twice daily and oral steroids were tapered to 5 mg daily. The
patient was started on intravenous ganciclovir 250 mg twice
daily for 3 weeks and oral valganciclovir 900 mg twice daily
for 8 weeks. Intravitreal ganciclovir 0.05 mg/0.1 ml weekly
eight injections in each eye were given. At 2 months, vision
improved to counting finger 2 m in the right eye and six
ninths in the left eye. Haemorrhages and exudates along the
inferior arcade disappeared in the left eye. The right eye
lesion, although, became smaller significantly but did not
disappear completely (Fig. 2); hence, oral valganciclovir and
intravitreal weekly ganciclovir was continued. Within
15 days, the lesions in the right eye started increasing and
the borders of the lesions got fuzzier (Fig. 3). The vision was
counting finger 1 metre. For this clinically resistant CMV
retinitis, intravitreal 2.4 mg/0.1 ml foscarnet was given in the
right eye biweekly and weekly in the left eye for 3 weeks. In
addition, the intravenous ganciclovir 250 mg was given
twice daily and the oral valganciclovir 900 mg twice daily
Fig. 3 The lesions in the right eye started increasing and the borders
of the lesions got fuzzier
Fig. 4 The lesions in both eyes
healed completely
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healed completely in the right eye (Fig. 4).The vision in the
right eye was 2 m and in the left eye was 20/20.Oral
valganciclovir was discontinued 1 month after complete
resolution of the ocular lesions. No recurrences were noted
up to 6 months.
Discussion
CMVretinitisinpatientswithoutHIVinfectionhaveaclinical
course similar to that in patients with AIDS treated with
highly active antiretroviral therapy. A substantial number of
non-HIV patients do not require long-term anti-CMV therapy
after adjustment of immunomodulatory therapy [2].
A patient with inactive SLE on mild immunosuppression
without systemic manifestations of CMV infection has been
reported before [3]. SLE, per se, does not seem to be the
primary predisposing factor for the development of CMV
retinitis [1]. Cytomegalovirus is a ubiquitous virus, and
primary exposure usually occurs at an early age. However,
clinical signs of infection usually do not manifest in
immunocompetent individuals. Adult-onset CMV disease
may occur as a result of primary infection, reinfection or
activation of a latent infection [4].
At the time when our patient was diagnosed as having
CMV retinitis, she was not experiencing an acute lupus
flare, and therefore it was possible to discontinue myco-
phenolate mofetil and reduce the dose of azathioprine and
oral steroids after consultation with the physician.
Intravitreal injections of ganciclovir are useful for the
non-HIV immunocompromised patients with CMV retinitis
[5]. Therapy with a combination of intravitreal foscarnet
and intravenous ganciclovir in clinically resistant CMV
retinitis in patients with acquired immunodeficiency syn-
drome has been reported [6].
In our patient with clinically resistant CMV retinitis,
discontinuation of mycophenolate mofetil and reduction of
the dose of Azathioprine and oral steroids in addition to
systemic and intravitreal ganciclovir therapy brought the
disease process well under control, but the lesions in the
right eye showed signs of resurgence and therefore a
combination of intravitreal foscarnet along with intravenous
ganciclovir and oral valganciclovir were given. The lesions
resolved completely.There was no evidence of reactivation
up to 6 months.
Conclusion
CMV retinitis is a rapidly progressive condition and
patients on immunosuppressive therapy should be referred
to an ophthalmologist for periodic check-up for early
diagnosis and treatment of this devastating ophthalmic
condition. For clinically resistant CMV retinitis in seroneg-
ative patients with SLE, a combination therapy of intra-
vitreal foscarnet with oral and intravenous ganciclovir is
useful.
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